Simplex Trading’s Oncternal Therapeutics ONCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-356
Closed -$5K – 10269
2023
Q1
$5K Sell
356
-24
-6% -$472 ﹤0.01% 8111
2022
Q4
$7K Buy
380
+114
+43% +$2.27K ﹤0.01% 7885
2022
Q3
$4K Sell
266
-2,808
-91% -$60.2K ﹤0.01% 9003
2022
Q2
$68K Buy
3,074
+1,272
+71% +$28.4K ﹤0.01% 6084
2022
Q1
$50K Buy
1,802
+1,307
+264% +$47.6K ﹤0.01% 7144
2021
Q4
$22K Sell
495
-1,889
-79% -$127K ﹤0.01% 8280
2021
Q3
$226K Hold
2,384
– – ﹤0.01% 5407
2021
Q2
$226K Buy
2,384
+466
+24% +$55.3K ﹤0.01% 5496
2021
Q1
$319K Buy
1,918
+1,751
+1,049% +$232K ﹤0.01% 4075
2020
Q4
$16K Buy
+167
New +$10.6K ﹤0.01% 7137
2018
Q3
– Sell
-2
Closed -$4.8K – 8248
2018
Q2
$3K Buy
+2
New +$5.07K ﹤0.01% 6967
2017
Q3
– Sell
-18
Closed -$13K – 6841
2017
Q2
$13K Buy
+18
New +$11K ﹤0.01% 3759
2017
Q1
– Hold
0
– – – 6944
2016
Q4
– Hold
0
– – – 6719
2016
Q1
– Sell
-2
Closed -$2K – 6424
2015
Q4
$2K Hold
2
– – ﹤0.01% 4640
2015
Q3
$2K Sell
2
-3
-60% -$4.38K ﹤0.01% 4773
2015
Q2
$10K Buy
5
+3
+150% +$4.26K ﹤0.01% 3084
2015
Q1
$2K Hold
2
– – ﹤0.01% 4234
2014
Q4
$2K Buy
+2
New +$1.78K ﹤0.01% 3853

Other funds holding ONCT

Simplex Trading's ONCT Position: Q2 2023 in Review

Simplex Trading sold out of Oncternal Therapeutics (ONCT) in Q2 2023, closing a stake of 356 shares — an estimated $5K sold.

Simplex Trading first reported a position in ONCT in Q4 2014 and held it in 17 quarters. The position peaked at $319K in Q1 2021. 52 funds tracked by Wall St. Rank hold ONCT as of Q2 2023.

  • Simplex Trading reported no remaining Oncternal Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Simplex Trading sold 356 Oncternal Therapeutics shares in Q2 2023, an estimated $5K.
  • Simplex Trading first reported a position in Oncternal Therapeutics in Q4 2014 and held it in 17 quarters.
  • Simplex Trading's Oncternal Therapeutics position peaked at $319K in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.